Protagonist Therapeutics Inc’s recently made public that its CEO Dinesh Patel acquired Company’s shares for reported $2.76 million on Jul 22 ’25. In the deal valued at $55.22 per share,50,000 shares were bought.
Then, MOLINA ARTURO MD sold 10,000 shares, generating $570,300 in total proceeds. Upon selling the shares at $57.03, the Chief Medical Officer now owns 83,892 shares.
Before that, MOLINA ARTURO MD sold 10,000 shares. Protagonist Therapeutics Inc shares valued at $555,100 were divested by the Chief Medical Officer at a price of $55.51 per share. As a result of the transaction, MOLINA ARTURO MD now holds 83,892 shares, worth roughly $4.61 million.
Citigroup initiated its Protagonist Therapeutics Inc [PTGX] rating to a Buy in a research note published on June 17, 2025; the price target was $72. A number of analysts have revised their coverage, including Goldman’s analysts, who began to cover the stock in early December with a ‘”a Neutral”‘ rating. BMO Capital Markets began covering PTGX with “an Outperform” recommendation on December 06, 2024. Wedbush started covering the stock on November 05, 2024. It rated PTGX as “an Outperform”.
Price Performance Review of PTGX
On Tuesday, Protagonist Therapeutics Inc [NASDAQ:PTGX] saw its stock fall -0.42% to $54.99. Over the last five days, the stock has lost -0.60%. Protagonist Therapeutics Inc shares have risen nearly 53.99% since the year began. Nevertheless, the stocks have risen 42.46% over the past one year. While a 52-week high of $60.60 was reached on 03/12/25, a 52-week low of $32.50 was recorded on 02/25/25.
Levels Of Support And Resistance For PTGX Stock
The 24-hour chart illustrates a support level at 54.43, which if violated will result in even more drops to 53.86. On the upside, there is a resistance level at 55.41. A further resistance level may holdings at 55.82.
How much short interest is there in Protagonist Therapeutics Inc?
A steep rise in short interest was recorded in Protagonist Therapeutics Inc stocks on 2025-06-30, growing by 1.52 million shares to a total of 6.73 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-30 was 5.21 million shares. There was a rise of 22.62%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on September 24, 2024 when TD Cowen began covering the stock and recommended ‘”a Buy”‘ rating along with a $65 price target.
